CDKN2A and sarcoma: Through integrated multi-omics and functional analyses, researchers discovered that TFCP2-rearranged sarcomas have a methylation profile more similar to undifferentiated sarcomas than RMS, exhibit high genomic instability and aberrant ALK kinase expression, and harbor co-deletions of CDKN2A/MTAP—findings that both advance our understanding of tumor biology and lay the groundwork for exploring new therapeutic strategies.